Does the media favor HAE or TNDM?

In the previous week, Tandem Diabetes Care had 1 more articles in the media than Haemonetics. MarketBeat recorded 5 mentions for Tandem Diabetes Care and 4 mentions for Haemonetics. Tandem Diabetes Care's average media sentiment score of 1.51 beat Haemonetics' score of 0.94 indicating that Tandem Diabetes Care is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Haemonetics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tandem Diabetes Care 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor LIVN or TNDM?

In the previous week, LivaNova had 2 more articles in the media than Tandem Diabetes Care. MarketBeat recorded 7 mentions for LivaNova and 5 mentions for Tandem Diabetes Care. Tandem Diabetes Care's average media sentiment score of 1.51 beat LivaNova's score of 0.88 indicating that Tandem Diabetes Care is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LivaNova 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tandem Diabetes Care 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor ITGR or TNDM?

In the previous week, Integer had 2 more articles in the media than Tandem Diabetes Care. MarketBeat recorded 7 mentions for Integer and 5 mentions for Tandem Diabetes Care. Tandem Diabetes Care's average media sentiment score of 1.51 beat Integer's score of 0.20 indicating that Tandem Diabetes Care is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Integer 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Tandem Diabetes Care 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to TNDM or IRTC?

In the previous week, Tandem Diabetes Care had 2 more articles in the media than iRhythm Technologies. MarketBeat recorded 5 mentions for Tandem Diabetes Care and 3 mentions for iRhythm Technologies. Tandem Diabetes Care's average media sentiment score of 1.51 beat iRhythm Technologies' score of 1.44 indicating that Tandem Diabetes Care is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tandem Diabetes Care 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive iRhythm Technologies 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer PLSE or TNDM?

In the previous week, Pulse Biosciences had 8 more articles in the media than Tandem Diabetes Care. MarketBeat recorded 13 mentions for Pulse Biosciences and 5 mentions for Tandem Diabetes Care. Tandem Diabetes Care's average media sentiment score of 1.51 beat Pulse Biosciences' score of 0.94 indicating that Tandem Diabetes Care is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pulse Biosciences 4 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tandem Diabetes Care 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Tandem Diabetes Care (TNDM) Competitors

$17.11 -1.20 (-6.55%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$17.17 +0.06 (+0.34%)

As of 09/11/2026 07:50 PM Eastern

Compare

TNDM vs. HAE, LIVN, ITGR, IRTC, and PLSE

Should you buy Tandem Diabetes Care stock or one of its competitors? Tandem Diabetes Care's main competitors and comparable companies include Haemonetics (HAE), LivaNova (LIVN), Integer (ITGR), iRhythm Technologies (IRTC), and Pulse Biosciences (PLSE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Tandem Diabetes Care compare to Haemonetics?

Haemonetics (NYSE:HAE) and Tandem Diabetes Care (NASDAQ:TNDM) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, valuation, earnings, dividends and media sentiment.

Haemonetics has a net margin of 7.12% compared to Tandem Diabetes Care's net margin of -6.08%. Haemonetics' return on equity of 27.55% beat Tandem Diabetes Care's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Haemonetics	7.12%	27.55%	9.65%
Tandem Diabetes Care	-6.08%	-45.97%	-6.23%

In the previous week, Tandem Diabetes Care had 1 more articles in the media than Haemonetics. MarketBeat recorded 5 mentions for Tandem Diabetes Care and 4 mentions for Haemonetics. Tandem Diabetes Care's average media sentiment score of 1.51 beat Haemonetics' score of 0.94 indicating that Tandem Diabetes Care is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Haemonetics	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tandem Diabetes Care	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Haemonetics has higher revenue and earnings than Tandem Diabetes Care. Tandem Diabetes Care is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Haemonetics	$1.35B	3.45	$97.31M	$2.04	50.32
Tandem Diabetes Care	$1.04B	1.14	-$204.71M	-$0.93	N/A

Haemonetics presently has a consensus price target of $99.78, suggesting a potential downside of 2.80%. Tandem Diabetes Care has a consensus price target of $29.34, suggesting a potential upside of 71.49%. Given Tandem Diabetes Care's higher possible upside, analysts plainly believe Tandem Diabetes Care is more favorable than Haemonetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Haemonetics	0 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.73
Tandem Diabetes Care	1 Sell rating(s)	11 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.48

Haemonetics has a beta of 0.54, suggesting that its share price is 46% less volatile than the broader market. Comparatively, Tandem Diabetes Care has a beta of 1.55, suggesting that its share price is 55% more volatile than the broader market.

99.7% of Haemonetics shares are held by institutional investors. 2.1% of Haemonetics shares are held by insiders. Comparatively, 2.1% of Tandem Diabetes Care shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Haemonetics beats Tandem Diabetes Care on 10 of the 16 factors compared between the two stocks.

How does Tandem Diabetes Care compare to LivaNova?

LivaNova (NASDAQ:LIVN) and Tandem Diabetes Care (NASDAQ:TNDM) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, media sentiment, analyst recommendations, institutional ownership and profitability.

Tandem Diabetes Care has lower revenue, but higher earnings than LivaNova. Tandem Diabetes Care is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LivaNova	$1.39B	3.10	-$242.47M	$3.38	23.13
Tandem Diabetes Care	$1.04B	1.14	-$204.71M	-$0.93	N/A

LivaNova currently has a consensus price target of $84.13, indicating a potential upside of 7.60%. Tandem Diabetes Care has a consensus price target of $29.34, indicating a potential upside of 71.49%. Given Tandem Diabetes Care's higher probable upside, analysts plainly believe Tandem Diabetes Care is more favorable than LivaNova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LivaNova	0 Sell rating(s)	5 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.55
Tandem Diabetes Care	1 Sell rating(s)	11 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.48

LivaNova has a beta of 0.87, meaning that its share price is 13% less volatile than the broader market. Comparatively, Tandem Diabetes Care has a beta of 1.55, meaning that its share price is 55% more volatile than the broader market.

In the previous week, LivaNova had 2 more articles in the media than Tandem Diabetes Care. MarketBeat recorded 7 mentions for LivaNova and 5 mentions for Tandem Diabetes Care. Tandem Diabetes Care's average media sentiment score of 1.51 beat LivaNova's score of 0.88 indicating that Tandem Diabetes Care is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LivaNova	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tandem Diabetes Care	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

LivaNova has a net margin of 12.82% compared to Tandem Diabetes Care's net margin of -6.08%. LivaNova's return on equity of 16.35% beat Tandem Diabetes Care's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LivaNova	12.82%	16.35%	7.76%
Tandem Diabetes Care	-6.08%	-45.97%	-6.23%

97.6% of LivaNova shares are held by institutional investors. 0.4% of LivaNova shares are held by company insiders. Comparatively, 2.1% of Tandem Diabetes Care shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

LivaNova beats Tandem Diabetes Care on 10 of the 17 factors compared between the two stocks.

How does Tandem Diabetes Care compare to Integer?

Integer (NYSE:ITGR) and Tandem Diabetes Care (NASDAQ:TNDM) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends, earnings and media sentiment.

Integer has a beta of 0.62, indicating that its share price is 38% less volatile than the broader market. Comparatively, Tandem Diabetes Care has a beta of 1.55, indicating that its share price is 55% more volatile than the broader market.

Integer has higher revenue and earnings than Tandem Diabetes Care. Tandem Diabetes Care is trading at a lower price-to-earnings ratio than Integer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Integer	$1.85B	2.31	$102.81M	$3.66	34.44
Tandem Diabetes Care	$1.04B	1.14	-$204.71M	-$0.93	N/A

Integer presently has a consensus target price of $109.86, indicating a potential downside of 12.86%. Tandem Diabetes Care has a consensus target price of $29.34, indicating a potential upside of 71.49%. Given Tandem Diabetes Care's stronger consensus rating and higher probable upside, analysts plainly believe Tandem Diabetes Care is more favorable than Integer.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Integer	0 Sell rating(s)	13 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.07
Tandem Diabetes Care	1 Sell rating(s)	11 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.48

In the previous week, Integer had 2 more articles in the media than Tandem Diabetes Care. MarketBeat recorded 7 mentions for Integer and 5 mentions for Tandem Diabetes Care. Tandem Diabetes Care's average media sentiment score of 1.51 beat Integer's score of 0.20 indicating that Tandem Diabetes Care is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Integer	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tandem Diabetes Care	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

99.3% of Integer shares are owned by institutional investors. 1.1% of Integer shares are owned by company insiders. Comparatively, 2.1% of Tandem Diabetes Care shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Integer has a net margin of 6.97% compared to Tandem Diabetes Care's net margin of -6.08%. Integer's return on equity of 12.79% beat Tandem Diabetes Care's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Integer	6.97%	12.79%	6.48%
Tandem Diabetes Care	-6.08%	-45.97%	-6.23%

Summary

Integer beats Tandem Diabetes Care on 10 of the 17 factors compared between the two stocks.

How does Tandem Diabetes Care compare to iRhythm Technologies?

Tandem Diabetes Care (NASDAQ:TNDM) and iRhythm Technologies (NASDAQ:IRTC) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, media sentiment, dividends and valuation.

iRhythm Technologies has a net margin of -1.69% compared to Tandem Diabetes Care's net margin of -6.08%. iRhythm Technologies' return on equity of 10.11% beat Tandem Diabetes Care's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tandem Diabetes Care	-6.08%	-45.97%	-6.23%
iRhythm Technologies	-1.69%	10.11%	1.53%

iRhythm Technologies has lower revenue, but higher earnings than Tandem Diabetes Care. iRhythm Technologies is trading at a lower price-to-earnings ratio than Tandem Diabetes Care, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tandem Diabetes Care	$1.04B	1.14	-$204.71M	-$0.93	N/A
iRhythm Technologies	$747.14M	4.92	-$44.55M	-$0.43	N/A

Tandem Diabetes Care has a beta of 1.55, meaning that its stock price is 55% more volatile than the broader market. Comparatively, iRhythm Technologies has a beta of 1.31, meaning that its stock price is 31% more volatile than the broader market.

Tandem Diabetes Care presently has a consensus target price of $29.34, suggesting a potential upside of 71.49%. iRhythm Technologies has a consensus target price of $179.93, suggesting a potential upside of 61.47%. Given Tandem Diabetes Care's higher probable upside, equities research analysts plainly believe Tandem Diabetes Care is more favorable than iRhythm Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tandem Diabetes Care	1 Sell rating(s)	11 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.48
iRhythm Technologies	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	2.94

In the previous week, Tandem Diabetes Care had 2 more articles in the media than iRhythm Technologies. MarketBeat recorded 5 mentions for Tandem Diabetes Care and 3 mentions for iRhythm Technologies. Tandem Diabetes Care's average media sentiment score of 1.51 beat iRhythm Technologies' score of 1.44 indicating that Tandem Diabetes Care is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tandem Diabetes Care	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
iRhythm Technologies	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

iRhythm Technologies beats Tandem Diabetes Care on 9 of the 15 factors compared between the two stocks.

How does Tandem Diabetes Care compare to Pulse Biosciences?

Pulse Biosciences (NASDAQ:PLSE) and Tandem Diabetes Care (NASDAQ:TNDM) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, dividends, institutional ownership, media sentiment, analyst recommendations and earnings.

Pulse Biosciences presently has a consensus target price of $45.25, indicating a potential downside of 14.80%. Tandem Diabetes Care has a consensus target price of $29.34, indicating a potential upside of 71.49%. Given Tandem Diabetes Care's higher possible upside, analysts clearly believe Tandem Diabetes Care is more favorable than Pulse Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulse Biosciences	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Tandem Diabetes Care	1 Sell rating(s)	11 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.48

Pulse Biosciences has a beta of 1.63, indicating that its stock price is 63% more volatile than the broader market. Comparatively, Tandem Diabetes Care has a beta of 1.55, indicating that its stock price is 55% more volatile than the broader market.

77.0% of Pulse Biosciences shares are held by institutional investors. 74.0% of Pulse Biosciences shares are held by company insiders. Comparatively, 2.1% of Tandem Diabetes Care shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Pulse Biosciences had 8 more articles in the media than Tandem Diabetes Care. MarketBeat recorded 13 mentions for Pulse Biosciences and 5 mentions for Tandem Diabetes Care. Tandem Diabetes Care's average media sentiment score of 1.51 beat Pulse Biosciences' score of 0.94 indicating that Tandem Diabetes Care is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pulse Biosciences	4 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tandem Diabetes Care	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Tandem Diabetes Care has a net margin of -6.08% compared to Pulse Biosciences' net margin of -6,755.78%. Tandem Diabetes Care's return on equity of -45.97% beat Pulse Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pulse Biosciences	-6,755.78%	-94.42%	-79.96%
Tandem Diabetes Care	-6.08%	-45.97%	-6.23%

Pulse Biosciences has higher earnings, but lower revenue than Tandem Diabetes Care. Pulse Biosciences is trading at a lower price-to-earnings ratio than Tandem Diabetes Care, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulse Biosciences	$350K	10,502.12	-$72.78M	-$1.18	N/A
Tandem Diabetes Care	$1.04B	1.14	-$204.71M	-$0.93	N/A

Summary

Tandem Diabetes Care beats Pulse Biosciences on 9 of the 16 factors compared between the two stocks.

Get Tandem Diabetes Care News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TNDM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TNDM vs. The Competition

Export

Metric	Tandem Diabetes Care	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.27B	$5.38B	$7.13B	$12.72B
Dividend Yield	N/A	1.79%	2.56%	11.15%
P/E Ratio	-18.40	25.09	275.24	25.29
Price / Sales	1.14	82.90	655.99	98.94
Price / Cash	N/A	32.53	77.04	51.44
Price / Book	7.47	5.97	10.33	6.20
Net Income	-$204.71M	$150.75M	$3.50B	$358.50M
7 Day Performance	-14.02%	-2.83%	-3.32%	-2.35%
1 Month Performance	-27.01%	-3.09%	-0.41%	-2.77%
1 Year Performance	39.45%	9.34%	19.21%	7.63%

Tandem Diabetes Care Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TNDM Tandem Diabetes Care	2.6568 of 5 stars	$17.11 -6.6%	$29.34 +71.5%	+33.8%	$1.27B	$1.04B	N/A	2,500	News Coverage Positive News Analyst Forecast
HAE Haemonetics	1.8246 of 5 stars	$103.00 +0.1%	$99.78 -3.1%	+91.7%	$4.68B	$1.33B	50.49	3,009
LIVN LivaNova	2.666 of 5 stars	$81.92 flat	$84.13 +2.7%	+36.3%	$4.51B	$1.39B	24.24	3,300	News Coverage Positive News Insider Trade
ITGR Integer	2.5072 of 5 stars	$126.40 -0.1%	$109.86 -13.1%	+21.1%	$4.30B	$1.85B	34.54	11,000	Insider Trade Options Volume
IRTC iRhythm Technologies	3.8705 of 5 stars	$123.07 flat	$179.93 +46.2%	-38.4%	$4.06B	$747.14M	N/A	2,400	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TNDM) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Tandem Diabetes Care (TNDM) Competitors

TNDM vs. HAE, LIVN, ITGR, IRTC, and PLSE

How does Tandem Diabetes Care compare to Haemonetics?

Summary

How does Tandem Diabetes Care compare to LivaNova?

Summary

How does Tandem Diabetes Care compare to Integer?

Summary

How does Tandem Diabetes Care compare to iRhythm Technologies?

Summary

How does Tandem Diabetes Care compare to Pulse Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TNDM vs. The Competition

Tandem Diabetes Care Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Tandem Diabetes Care (TNDM) Competitors

TNDM vs. HAE, LIVN, ITGR, IRTC, and PLSE

How does Tandem Diabetes Care compare to Haemonetics?

Is HAE or TNDM more profitable?

Does the media favor HAE or TNDM?

Which has stronger valuation & earnings, HAE or TNDM?

Do analysts recommend HAE or TNDM?

Which has more risk and volatility, HAE or TNDM?

Do institutionals and insiders have more ownership in HAE or TNDM?

Summary

How does Tandem Diabetes Care compare to LivaNova?

Which has better earnings & valuation, LIVN or TNDM?

Do analysts prefer LIVN or TNDM?

Which has more volatility and risk, LIVN or TNDM?

Does the media favor LIVN or TNDM?

Is LIVN or TNDM more profitable?

Do institutionals and insiders hold more shares of LIVN or TNDM?

Summary

How does Tandem Diabetes Care compare to Integer?

Which has more volatility & risk, ITGR or TNDM?

Which has preferable earnings and valuation, ITGR or TNDM?

Do analysts recommend ITGR or TNDM?

Does the media favor ITGR or TNDM?

Do institutionals and insiders have more ownership in ITGR or TNDM?

Is ITGR or TNDM more profitable?

Summary

How does Tandem Diabetes Care compare to iRhythm Technologies?

Is TNDM or IRTC more profitable?

Which has higher valuation & earnings, TNDM or IRTC?

Which has more volatility and risk, TNDM or IRTC?

Do analysts prefer TNDM or IRTC?

Does the media refer more to TNDM or IRTC?

Summary

How does Tandem Diabetes Care compare to Pulse Biosciences?

Do analysts prefer PLSE or TNDM?

Which has more risk & volatility, PLSE or TNDM?

Do insiders and institutionals believe in PLSE or TNDM?

Does the media prefer PLSE or TNDM?

Is PLSE or TNDM more profitable?

Which has preferable valuation and earnings, PLSE or TNDM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TNDM vs. The Competition

Tandem Diabetes Care Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools